{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T23:03:29Z","timestamp":1789513409496,"version":"build-2803163510"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:00:00Z","timestamp":1782172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:00:00Z","timestamp":1789516800000},"content-version":"vor","delay-in-days":85,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["RS-2021-NR058556"],"award-info":[{"award-number":["RS-2021-NR058556"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-59002-y","type":"journal-article","created":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T10:46:27Z","timestamp":1782211587000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Emetine dihydrochloride suppresses the invasiveness and motility of hepatocellular carcinoma cells through MAPK pathway inhibition and Twist1 protein destabilization"],"prefix":"10.1038","volume":"16","author":[{"given":"Haelim","family":"Yoon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eunjeong","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gyun Seok","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sayeon","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,23]]},"reference":[{"key":"59002_CR1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray, F. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 68, 394\u2013424. https:\/\/doi.org\/10.3322\/caac.21492 (2018).","journal-title":"CA Cancer J. Clin."},{"key":"59002_CR2","doi-asserted-by":"publisher","first-page":"4475","DOI":"10.1002\/cncr.25960","volume":"117","author":"K Uchino","year":"2011","unstructured":"Uchino, K. et al. Hepatocellular carcinoma with extrahepatic metastasis: Clinical features and prognostic factors. Cancer 117, 4475\u20134483. https:\/\/doi.org\/10.1002\/cncr.25960 (2011).","journal-title":"Cancer"},{"key":"59002_CR3","doi-asserted-by":"publisher","first-page":"23265","DOI":"10.18632\/oncotarget.15575","volume":"8","author":"Y Cheng","year":"2017","unstructured":"Cheng, Y. et al. Synergistic anti-tumor efficacy of sorafenib and fluvastatin in hepatocellular carcinoma. Oncotarget 8, 23265. https:\/\/doi.org\/10.18632\/oncotarget.15575 (2017).","journal-title":"Oncotarget"},{"issue":"7","key":"59002_CR4","doi-asserted-by":"publisher","first-page":"345","DOI":"10.4254\/wjh.v5.i7.345","volume":"5","author":"B Zhai","year":"2013","unstructured":"Zhai, B. & Sun, X.-Y. Mechanisms of resistance to sorafenib and the corresponding strategies in hepatocellular carcinoma. World J.\u00a0Hepatol. 5, 345-357.\u00a0https:\/\/doi.org\/10.4254\/wjh.v5.i7.345 (2013).","journal-title":"World J. Hepatol."},{"key":"59002_CR5","doi-asserted-by":"publisher","first-page":"3069","DOI":"10.1200\/JCO.2006.08.4046","volume":"25","author":"A Croitoru","year":"2007","unstructured":"Croitoru, A. et al. Phase III randomized controlled trial comparing the survival of patients with unresectable hepatocellular carcinoma treated with nolatrexed or doxorubicin. J. Clin. Oncol. 25, 3069\u20133075. https:\/\/doi.org\/10.18632\/oncotarget.15575 (2007).","journal-title":"J. Clin. Oncol."},{"key":"59002_CR6","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1001\/jama.2010.1672","volume":"304","author":"GK Abou-Alfa","year":"2010","unstructured":"Abou-Alfa, G. K. et al. Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: A randomized trial. JAMA 304, 2154\u20132160.\u00a0https:\/\/doi.org\/10.1001\/jama.2010.1672 (2010).","journal-title":"JAMA"},{"key":"59002_CR7","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0065569","author":"M Cervello","year":"2013","unstructured":"Cervello, M. et al. Novel combination of sorafenib and celecoxib provides synergistic anti-proliferative and pro-apoptotic effects in human liver cancer cells. PLoS ONE\u00a08, e65569.\u00a0https:\/\/doi.org\/10.1371\/journal.pone.0065569 (2013).","journal-title":"PLoS ONE"},{"key":"59002_CR8","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.1080\/15384047.2015.1099769","volume":"16","author":"T Webb","year":"2015","unstructured":"Webb, T. et al. Celecoxib enhances [sorafenib + sildenafil] lethality in cancer cells and reverts platinum chemotherapy resistance. Cancer Biol. Ther. 16, 1660\u20131670.\u00a0https:\/\/doi.org\/10.1080\/15384047.2015.1099769 (2015).","journal-title":"Cancer Biol. Ther."},{"key":"59002_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.29219\/fnr.v65.3602","volume":"65","author":"M Gao","year":"2021","unstructured":"Gao, M., Deng, C. & Dang, F. Synergistic antitumor effect of resveratrol and sorafenib on hepatocellular carcinoma through PKA\/AMPK\/eEF2K pathway. Food Nutr. Res. 65, 1\u201314.\u00a0https:\/\/doi.org\/10.29219\/fnr.v65.3602  (2021).","journal-title":"Food Nutr. Res."},{"key":"59002_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40169-015-0048-3","volume":"4","author":"S Heerboth","year":"2015","unstructured":"Heerboth, S. et al. EMT and tumor metastasis. Clin. Transl. Med. 4, e6.\u00a0https:\/\/doi.org\/10.1186\/s40169-015-0048-3 (2015).","journal-title":"Clin. Transl. Med."},{"key":"59002_CR11","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1016\/j.jhep.2016.05.007","volume":"65","author":"G Giannelli","year":"2016","unstructured":"Giannelli, G., Koudelkova, P., Dituri, F. & Mikulits, W. Role of epithelial to mesenchymal transition in hepatocellular carcinoma. J. Hepatol. 65, 798\u2013808.\u00a0https:\/\/doi.org\/10.1016\/j.jhep.2016.05.007  (2016).","journal-title":"J. Hepatol."},{"key":"59002_CR12","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.2005189","volume":"7","author":"DM Gonzalez","year":"2014","unstructured":"Gonzalez, D. M. & Medici, D. Signaling mechanisms of the epithelial-mesenchymal transition. Sci. Signal. 7, re8.\u00a0https:\/\/doi.org\/10.1126\/scisignal.2005189 (2014).","journal-title":"Sci. Signal."},{"key":"59002_CR13","doi-asserted-by":"publisher","first-page":"3591","DOI":"10.3390\/ijms22073591","volume":"22","author":"E Kang","year":"2021","unstructured":"Kang, E., Seo, J., Yoon, H. & Cho, S. The post-translational regulation of epithelial\u2013mesenchymal transition-inducing transcription factors in cancer metastasis. Int. J. Mol. Sci. 22, 3591.\u00a0https:\/\/doi.org\/10.3390\/ijms22073591\u00a0(2021).","journal-title":"Int. J. Mol. Sci."},{"key":"59002_CR14","doi-asserted-by":"publisher","first-page":"20380","DOI":"10.18632\/oncotarget.14608","volume":"8","author":"Z Zhao","year":"2017","unstructured":"Zhao, Z., Rahman, M. A., Chen, Z. G. & Shin, D. M. Multiple biological functions of Twist1 in various cancers. Oncotarget 8, 20380\u201320393.\u00a0https:\/\/doi.org\/10.18632\/oncotarget.14608 \u00a0(2017).","journal-title":"Oncotarget"},{"key":"59002_CR15","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1002\/hep.23311","volume":"51","author":"T Sun","year":"2010","unstructured":"Sun, T. et al. Expression and functional significance of Twist1 in hepatocellular carcinoma: Its role in vasculogenic mimicry. Hepatology 51, 545\u2013556.\u00a0https:\/\/doi.org\/10.1002\/hep.23311\u00a0(2010).","journal-title":"Hepatology"},{"key":"59002_CR16","doi-asserted-by":"publisher","DOI":"10.3390\/ph13030051","author":"MD Bleasel","year":"2020","unstructured":"Bleasel, M. D. & Peterson, G. M. Emetine, ipecac, ipecac alkaloids and analogues as potential antiviral agents for coronaviruses. Pharmaceuticals 13, 51.\u00a0https:\/\/doi.org\/10.3390\/ph13030051 (2020).","journal-title":"Pharmaceuticals"},{"key":"59002_CR17","doi-asserted-by":"publisher","first-page":"8","DOI":"10.2174\/1874848101104010008","volume":"4","author":"ES Akinboye","year":"2011","unstructured":"Akinboye, E. S. & Bakare, O. Biological activities of emetine. Open Nat. Prod. J. 4, 8\u201315.\u00a0https:\/\/doi.org\/10.2174\/1874848101104010008 (2011).","journal-title":"Open Nat. Prod. J."},{"key":"59002_CR18","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1016\/j.juro.2013.09.014","volume":"191","author":"KE Foreman","year":"2014","unstructured":"Foreman, K. E., Jesse, J. N., Kuo, P. C. & Gupta, G. N. Emetine dihydrochloride: A novel therapy for bladder cancer. J. Urol. 191, 502\u2013509.\u00a0https:\/\/doi.org\/10.1016\/j.juro.2013.09.014 (2014).","journal-title":"J. Urol."},{"key":"59002_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2021.105056","author":"R Kumar","year":"2021","unstructured":"Kumar, R. et al. Emetine suppresses SARS-CoV-2 replication by inhibiting interaction of viral mRNA with eIF4E. Antivir. Res.189, 105056.\u00a0https:\/\/doi.org\/10.1016\/j.antiviral.2021.105056 (2021).","journal-title":"Antivir. Res."},{"key":"59002_CR20","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1002\/1097-0142(197104)27:4<835::AID-CNCR2820270413>3.0.CO;2-K","volume":"27","author":"F Panettiere","year":"1971","unstructured":"Panettiere, F. & Coltman, C. A. Phase I experience with emetine hydrochloride (NSC 33669) as an antitumor agent. Cancer 27, 835\u2013841   (1971).","journal-title":"Cancer"},{"key":"59002_CR21","doi-asserted-by":"publisher","first-page":"389","DOI":"10.3892\/ijo.2014.2703","volume":"46","author":"Q Sun","year":"2015","unstructured":"Sun, Q., Yogosawa, S., Iizumi, Y., Sakai, T. & Sowa, Y. The alkaloid emetine sensitizes ovarian carcinoma cells to cisplatin through downregulation of bcl-xL. Int. J. Oncol. 46, 389\u2013394.\u00a0https:\/\/doi.org\/10.3892\/ijo.2014.2703 (2015).","journal-title":"Int. J. Oncol."},{"key":"59002_CR22","doi-asserted-by":"publisher","first-page":"323","DOI":"10.17179\/excli2016-280","volume":"15","author":"PF Uzor","year":"2016","unstructured":"Uzor, P. F. Recent developments on potential new applications of emetine as anti-cancer agent. EXCLI J. 15, 323\u2013328.\u00a0https:\/\/doi.org\/10.17179\/excli2016-280 (2016).","journal-title":"EXCLI J."},{"key":"59002_CR23","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/S0140-6736(72)91771-0","volume":"300","author":"EW Street","year":"1972","unstructured":"Street, E. W. Cyclophosphamide plus emetine in lung cancer. Lancet 300, 381\u2013382.\u00a0https:\/\/doi.org\/10.17179\/excli2016-280 (1972).","journal-title":"Lancet"},{"key":"59002_CR24","doi-asserted-by":"publisher","first-page":"2796","DOI":"10.1038\/onc.2009.139","volume":"28","author":"S Mori","year":"2009","unstructured":"Mori, S. et al. Anchorage-independent cell growth signature identifies tumors with metastatic potential. Oncogene 28, 2796\u20132805.\u00a0https:\/\/doi.org\/10.1038\/onc.2009.139 (2009).","journal-title":"Oncogene"},{"key":"59002_CR25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0044640","author":"WY Ho","year":"2012","unstructured":"Ho, W. Y., Yeap, S. K., Ho, C. L., Rahim, R. A. & Alitheen, N. B. Development of multicellular tumor spheroid (MCTS) culture from breast cancer cell and a high throughput screening method using the MTT assay.PLoS ONE7, e44640.https:\/\/doi.org\/10.1371\/journal.pone.0044640 (2012).","journal-title":"PLoS ONE"},{"key":"59002_CR26","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s10555-008-9169-0","volume":"28","author":"M Yilmaz","year":"2009","unstructured":"Yilmaz, M. & Christofori, G. EMT, the cytoskeleton, and cancer cell invasion. Cancer Metastasis Rev. 28, 15\u201333.\u00a0https:\/\/doi.org\/10.1007\/s10555-008-9169-0 (2009).","journal-title":"Cancer Metastasis Rev."},{"key":"59002_CR27","doi-asserted-by":"publisher","DOI":"10.3390\/s18103249","author":"H Huang","year":"2018","unstructured":"Huang, H. Matrix metalloproteinase-9 (MMP-9) as a cancer biomarker and MMP-9 biosensors: Recent advances. Sensors 18, 3249.\u00a0https:\/\/doi.org\/10.3390\/s18103249 (2018).","journal-title":"Sensors"},{"key":"59002_CR28","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1038\/s41586-019-1707-0","volume":"575","author":"S Doll","year":"2019","unstructured":"Doll, S. et al. FSP1 is a glutathione-independent ferroptosis suppressor. Nature 575, 693\u2013698.\u00a0https:\/\/doi.org\/10.1038\/s41586-019-1707-0 (2019).","journal-title":"Nature"},{"key":"59002_CR29","doi-asserted-by":"publisher","first-page":"3980","DOI":"10.1158\/0008-5472.CAN-10-2914","volume":"71","author":"J Hong","year":"2011","unstructured":"Hong, J. et al. Phosphorylation of serine 68 of Twist1 by MAPKs stabilizes twist1 protein and promotes breast cancer cell invasiveness. Cancer Res. 71, 3980.\u00a0https:\/\/doi.org\/10.1158\/0008-5472.CAN-10-2914 (2011).","journal-title":"Cancer Res."},{"key":"59002_CR30","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/S0076-6879(05)07047-3","volume":"407","author":"L Adnane","year":"2006","unstructured":"Adnane, L., Trail, P. A., Taylor, I. & Wilhelm, S. M. Sorafenib (BAY 43\u20139006, Nexavar\u00ae), a dual-action inhibitor that targets RAF\/MEK\/ERK pathway in tumor cells and tyrosine kinases VEGFR\/PDGFR in tumor vasculature. Methods Enzymol. 407, 597\u2013612.\u00a0https:\/\/doi.org\/10.1016\/S0076-6879(05)07047-3 (2006).","journal-title":"Methods Enzymol."},{"key":"59002_CR31","doi-asserted-by":"publisher","first-page":"10871","DOI":"10.1038\/s41598-019-47416-w","volume":"9","author":"Y Shichi","year":"2019","unstructured":"Shichi, Y. et al. Enhanced morphological and functional differences of pancreatic cancer with epithelial or mesenchymal characteristics in 3D culture. Sci. Rep. 9, 10871.\u00a0https:\/\/doi.org\/10.1038\/s41598-019-47416-w (2019).","journal-title":"Sci. Rep."},{"key":"59002_CR32","doi-asserted-by":"publisher","first-page":"6775","DOI":"10.1038\/s41598-021-86028-1","volume":"11","author":"F Minami","year":"2021","unstructured":"Minami, F. et al. Morphofunctional analysis of human pancreatic cancer cell lines in 2- and 3-dimensional cultures. Sci. Rep. 11, 6775.\u00a0https:\/\/doi.org\/10.1038\/s41598-021-86028-1 (2021).","journal-title":"Sci. Rep."},{"key":"59002_CR33","doi-asserted-by":"publisher","first-page":"702","DOI":"10.3390\/cells11040702","volume":"11","author":"GI Khandakar","year":"2022","unstructured":"Khandakar, G. I. et al. ACAGT-007a, an ERK MAPK signaling modulator, in combination with AKT signaling inhibition induces apoptosis in KRAS mutant pancreatic cancer T3M4 and MIA-Pa-Ca-2 cells. Cells 11, 702.\u00a0https:\/\/doi.org\/10.3390\/cells11040702 (2022).","journal-title":"Cells"},{"key":"59002_CR34","doi-asserted-by":"publisher","first-page":"11","DOI":"10.4078\/jrd.2018.25.1.11","volume":"25","author":"C-H Lee","year":"2018","unstructured":"Lee, C.-H. & Choi, E. Y. Macrophages and Inflammation. J. Rheum. Dis. 25, 11\u201318.\u00a0https:\/\/doi.org\/10.4078\/jrd.2018.25.1.11 (2018).","journal-title":"J. Rheum. Dis."},{"key":"59002_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2407-9-240","volume":"9","author":"N Matsuo","year":"2009","unstructured":"Matsuo, N. et al. Twist expression promotes migration and invasion in hepatocellular carcinoma. BMC Cancer 9, 1\u201312.\u00a0https:\/\/doi.org\/10.1186\/1471-2407-9-240 (2009).","journal-title":"BMC Cancer"},{"key":"59002_CR36","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.bjorl.2019.10.009","volume":"87","author":"Z Song","year":"2021","unstructured":"Song, Z. et al. The role of MMP-2 and MMP-9 in the metastasis and development of hypopharyngeal carcinoma. Braz. J. Otorhinolaryngol. 87, 521\u2013528.\u00a0https:\/\/doi.org\/10.1016\/j.bjorl.2019.10.009 (2021).","journal-title":"Braz. J. Otorhinolaryngol."},{"key":"59002_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.gep.2020.119127","volume":"37","author":"S Ardalan Khales","year":"2020","unstructured":"Ardalan Khales, S., Abbaszadegan, M. R., Majd, A. & Forghanifard, M. M. TWIST1 upregulates matrix metalloproteinase (MMP) genes family in esophageal squamous carcinoma cells. Gene Expr. Patterns 37, 119127.\u00a0https:\/\/doi.org\/10.1016\/j.gep.2020.119127 (2020).","journal-title":"Gene Expr. Patterns"},{"key":"59002_CR38","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.cbi.2015.08.014","volume":"242","author":"JH Kim","year":"2015","unstructured":"Kim, J. H. et al. Emetine inhibits migration and invasion of human non-small-cell lung cancer cells via regulation of ERK and p38 signaling pathways. Chem. Biol. Interact. 242, 25\u201333.\u00a0https:\/\/doi.org\/10.21203\/rs.3.rs-4805487\/v1 (2015).","journal-title":"Chem. Biol. Interact."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-59002-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-59002-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-59002-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T22:29:59Z","timestamp":1789511399000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-59002-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,23]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["59002"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-59002-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,23]]},"assertion":[{"value":"5 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"28779"}}